The global hypertension drugs market is estimated to have reached $24.7bn in 2018 and is expected to reach the market value of $19.3bn by 2029 with a CAGR of -2.3% from 2019 to 2029.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 146-page report you will receive 118 charts– all unavailable elsewhere.
The 146-page report provides clear detailed insight into the hypertension drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Hypertension Drugs Market forecasts from 2019-2029
• Global Pulmonary Arterial Hypertension (PAH) Market forecasts from 2019-2029
• Revenue forecasts for the Hypertension Drugs by Class of Drug from 2019-2029:
• Angiotensin II Receptor Blockers (ARBs): further broken down into revenue forecast of Atacand, Avapro, Diovan, Cozaar, Benicar, Entresto, Micardis, Azilva, Candesartan
• Angiotensin-converting Enzyme (ACE) Inhibitor: further broken down into revenue forecast of Tritace
• Beta-Blockers: further broken down into revenue forecast of Seloken/Toprol-XL, Coreg CR, Concor
• Calcium Channel Blockers (CCBs): further broken down into revenue forecast of Norvasc, Plendil, Adalat, Amlodin
• Diuretics
• Fixed-dose Combinations (FDC): further broken down into revenue forecast of Azor, Tribenzor, Exforge, Tekturna HCT, others
• Revenue forecasts for the leading PAH drugs from 2019-2029:
• Tacleer
• Uptravi
• Opsumit
• Letairis
• Adcirca
• Revatio
• Adempas
• Veletri
• Oremitram
• Tyvaso
• Remodulin
• Revenue forecasts for the Hypertension Drugs by Regional and National Market from 2019-2029:
• U.S.
• Canada
• Mexico
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Russia
• Japan
• China
• India
• Rest of Asia
• Brazil
• South Africa
• Rest of the World
• Profiles and discussion on the leading companies of the hypertension drugs market:
• Actelion
• AstraZeneca
• Boehringer Ingelheim GmbH
• Daiichi Sankyo
• Johnson & Johnson Company
• Merck & Co.
• Novartis
• Pfizer
• Sanofi Aventis
• United Therapeutics
• Analysis of the Drivers, Restraints, Opportunities and Porter’s Five Forces analysis of the global hypertension drugs market
• Key Questions Answered by this Report:
• How is the Hypertension Drugs market evolving?
• What is driving and restraining the Hypertension Drugs market dynamics?
• How will each of the submarkets grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each of the Hypertension Drugs submarkets develop from 2019 to 2029?
• What will be the main driver for the overall market from 2019-2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry sector evolve during the period between 2019 and 2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Hypertension Drugs Market. You find data, trends and predictions.
Buy our report today Hypertension Drugs Market Analysis of 2019-2029: Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs).
Visiongain is a trading partner with the US Federal Government
CCR Ref number KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com
1. Report Overview
1.1 Global Hypertension Drugs Market Overview
1.2 Overview of Findings
1.3 Global Hypertension Drugs Market Segmentation, 2019
1.4 Structure of the Report
1.5 How This Report Delivers
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to the Hypertension Drugs Market
2.1 An Overview of Hypertension
2.2 Causes of Hypertension
2.3 Primary Hypertension
2.4 Secondary Hypertension
2.5 Pulmonary Hypertension
2.6 Epidemiology of Hypertension
2.7 Links with Other Disorders
2.8 Treatment of Hypertension
2.9 Treatment Targets and the Selection of Drugs
3. Hypertension Drugs Market Overview, 2018
3.1 Market Definition and Segments covered:
3.2 Global Hypertension Drugs Market Segmentation
3.3 Market Size and Growth Prospects
3.4 Hypertension Drugs Market Dynamics (Drivers & Restraints)
3.4.1 Drivers
3.4.1.1 Rising Prevalence of Hypertension to boost the market growth
3.4.1.2 Rising complications of untreated blood pressure
3.4.1.3 Growing government and private initiatives to prevent and treat hypertension
3.4.2 Restraints
3.4.2.1 Tough generic competition due to patent expiry
3.4.2.2 Rising non-pharmacological treatment
3.4.3 Opportunities
3.4.3.1 Introduction of novel approaches for the treatment of hypertension
3.5 Hypertension Market Industry Analysis
3.5.1 Porter’s Five Force Analysis
3.5.1.1 Rivalry among Competitors [High]
3.5.1.2 Threat of New Entrants [Low]
3.5.1.3 Power of Suppliers [High]
3.5.1.4 Power of Buyers [Medium]
3.5.1.5 Threat of Substitutes [Low]
3.6 Value Chain Analysis
3.6.1 Manufacturer of medicine:
3.6.2 Wholesalers:
3.6.3 Pharmacy:
3.6.4 Health Plans and Pharmacy Benefit Managers (PBMs):
3.7 Opportunity Analysis
3.7.1 PAH (Pulmonary Arterial Hypertension Market)
4. Hypertension Drugs Market by Types, 2019-2029
4.1 Introduction
4.2 Beta Blockers
4.3 Angiotensin Converting Enzyme (ACE) Inhibitors
4.4 Calcium Channel Blockers (CCBs)
4.5 Angiotensin II Receptor Blocker (ARBs)
4.6 Diuretics
4.7 Fixed Dose Combination (FDCs)
4.8 Prospects for Hypertension Patients
5. Pulmonary Arterial Hypertension (PAH), 2019-2029
6. The Leading National Hypertension Drugs Market, 2019-2029
6.1 The Leading National Hypertension Drugs Market, 2018
6.2 The Leading National Hypertension Drugs Market, 2029
6.3 Leading National Hypertension Drugs Market Forecast, 2019-2029
6.4 The US Hypertension Drugs Market Forecast, 2019-2029
6.5 The Canadian Hypertension Drugs Market Forecast, 2019-2029
6.6 The Mexican Hypertension Drugs Market Forecast, 2019-2029
6.7 The European Hypertension Drugs Market, 2019-2029
6.7.1 EU Hypertension Drugs Market Forecast, 2019-2029
6.7.1.1 The German Hypertension Drugs Market Forecast 2019-2029
6.7.1.2 The French Hypertension Drugs Market Forecast 2019-2029
6.7.1.3 The UK Hypertension Drugs Market Forecast, 2019-2029
6.7.1.4 The Italian Hypertension Drugs Market Forecast, 2019-2029
6.7.1.5 The Spanish Hypertension Drugs Market Forecast, 2019-2029
6.7.1.6 Rest of Europe (RoE) Hypertension Drugs Market Forecast, 2019-2029
6.8 Japanese Hypertension Drugs Market Forecast, 2019-2029
6.9 The Chinese Hypertension Drugs Market Forecast, 2019-2029
6.10 The Indian Hypertension Drugs Market Forecast, 2019-2029
6.11 The Rest of Asia (ROA) Hypertension Drugs Market Forecast, 2019-2029
6.12 Russian Hypertension Drugs Market Forecast, 2019-2029
6.13 The Brazilian Hypertension Drugs Market Forecast, 2019-2029
6.14 South Africa Hypertension Drugs Market Forecast, 2019-2029
6.15 RoW Hypertension Drugs Market Forecast, 2019-2029
7. Leading Companies in Hypertension Drugs Market 2019-2029
7.1 Actelion (now a Johnson & Johnson company)
7.1.1 Financial Performance
7.1.2 Product Sales Performance
7.1.3 PAH Product Sales Performance
7.1.4 Merger and Acquisition
7.2 Johnson & Johnson Company
7.2.1 Merger and Acquisition
7.2.2 New Drug Development for Resistant Hypertension
7.3 AstraZeneca
7.3.1 Financial Performance
7.3.2 Financial Performance by Segments
7.3.3 Major Cardiovascular Products
7.3.4 Anti-Hypertension Products and Patent Status
7.3.5 Anti-Hypertension Products Sales by Region
7.3.6 Recent Developments
7.4 Sanofi Aventis
7.4.1 Financial Performance
7.4.1.1 Financial Performance by Segments
7.5 Daiichi Sankyo
7.5.1 Financial Performance
7.5.2 Products
7.6 Novartis
7.6.1 Financial Performance by Business Segments
7.6.2 Products
7.6.3 Pipeline Products
7.7 Pfizer
7.7.1 Pfizer Financial Performance, 2015-2017
7.7.2 Products- PAH
7.8 Merck & Co.
7.8.1 Merck &Co. Financial Performance, 2015-2017
7.9 Boehringer Ingelheim GmbH
7.9.1 Financial Performance, 2016-2017
7.10 United Therapeutics
7.10.1 Financial Performance, 2015-2017
7.10.2 Financial Performance by Geography, 2015-2017
8. Pipeline Developments in Hypertension
9. Conclusions & Recommendations
10. Key Findings
10.1 Market Snapshot: World Hypertension Drugs Market (2019 & 2029)
10.2 Market Drivers & Restraints
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1: Categories of Blood Pressure in Adults
Table 4.1 Global Beta Blockers Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.2 Leading Beta Blockers to treat Hypertension
Table 4.3 The Beta Blockers Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.4 The Beta Blockers Market Forecast by Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.5 The ACE Inhibitors Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.6 Leading ACE Inhibitors to treat Hypertension
Table 4.7 The ACE Inhibitor Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.8 The ACE Market Forecast by Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.9 The CCBs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.10 Leading Calcium Channel Blockers to treat Hypertension
Table 4.11 The CCBs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.12 The CCBs Generics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.13 The ARBs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.14 The ARBs Market Leading Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.15 Leading ARBs to treat Hypertension
Table 4.16 The ARBs Market Forecast of Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.17 The Diuretics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.18 The FDCS Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.19 The FDCs Market Leading Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 4.20 Leading FDCs to treat Hypertension
Table 4.21 The FDCs Market Forecast of Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 5.1 The PAH Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 5.2 The PAH Market Forecast for Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 5.3 The PAH Market Forecast for Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.1: The Hypertension Drugs Market by Country: Revenue ($bn), and Market Share (%), 2018
Table: 6.2 The Hypertension Drugs Market by Country: Revenue ($bn), 2029
Table 6.3 The Leading National Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.4 The US Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.5 Canada Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.6 Mexico Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.7 The European Hypertension Drugs Market by Country: Revenue ($bn) and Market Share (%), 2018
Table 6.8 EU Hypertension Drugs Market by Country Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.9 Germany Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and
Table: 6.10 France Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.11. UK Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.12 Italy Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.13 Spain Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.14 Rest of Europe (RoE) Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.15 Japan Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.16 China Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.17 India Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.18 RoA Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.19 Russia Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.20 Brazil Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.21 South Africa Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 6.22 RoW Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
Table 7.1 Actelion Revenue: Product Sales ($mn), Core R&D ($mn) and Operating Income ($mn), 2014-2016
Table 7.2 Actelion Revenue, Product Sales ($mn), 2015-2016
Table 7.3 Opsumit Revenue, Product Sales ($mn) by Region, 2015-2016
Table 7.4 Uptravi Revenue, Product Sales (USD mn), By Region, 2015-2016
Table 7.5 Veletri Revenue, Product Sales ($mn), By Region, 2015-2016
Table 7.6 Ventavis Revenue, Product Sales ($mn), By Region, 2015-2016
Table 7.7 J&J Pharmaceutical: Revenue ($bn), Revenue Share (%) by Segment, 2016 and 2017
Table 7.8 AstraZeneca Net Sales by Product Category, ($mn),2015-2017
Table 7.9 AstraZeneca’s Anti-Hypertension Drugs Portfolio and Patent Status
Table 7.10 AstraZeneca’s Anti-Hypertension Products Sales by Region, ($mn), 2015-2017
Table 7.11 Daiichi Sankyo Antihypertension Products by Business Units
Table 7.12 Novartis Pharmaceuticals by Division: Revenue ($mn), 2017
Table 7.13 Established Medicine by Division: Revenue ($mn), 2017 (Y-O-Y change in USD %)
Table 7.14 Novartis Pipeline Products for Hypertension and Clinical Trial Phase
Table 7.15 Pfizer by Division: Revenue ($mn),2015- 2017
Table 7.16 Pfizer by Geography: Revenue ($mn), 2015- 2017
Table 7.17 Pfizer for PAH: Revenue ($mn), 2015- 2017
Table 7.18 Merck & Co.: Revenue by Segments ($mn), 2015-2017
Table 7.19 Merck & Co.: Revenue, By Anti–Hypertension Products ($mn), 2015- 2017
Table 7.20 Merck & Co.: Cozaar Revenue by Geography ($mn), 2015- 2017
Table 7.21 Merck & Co.: Adempas Revenue by Geography ($mn),2015- 2017
Table 7.22 Boehringer Ingelheim: Revenue by Segments ($mn), 2015- 2017
Table 7.23 Boehringer Ingelheim: Revenue by Segments ($mn),2016- 2017
Table 7.24 Boehringer Ingelheim: Anti-Hypertension Revenue by Products ($mn), 2016- 2017
Table 7.25 United Therapeutics PAH Revenue by Products ($mn),2016- 2017
Table 7.26 United Therapeutics Revenue by Geography ($mn), 2015- 2017Table 10.1 Market Snapshot: World Ophthalmic devices Market (2019 & 2029)
List of Figures
Figure 1.1 Hypertension Drugs Market: Overview of Submarkets, 2019
Figure 3.1: Global Hypertension Drugs: Overview of Submarkets and Drugs /Classes, 2019
Figure 3.2: Global Hypertension Drugs Market: Drivers & Restraints, 2019
Figure 3.3: Porter’s Five Forces Analysis of the Hypertension Drugs Market
Figure 3.4: Value Chain Analysis Hypertension Drugs Market, 2019
Figure 4.1 Hypertension Drugs Market by Type of Drugs: Market Share (%), 2018
Figure 6.1 The Hypertension Drugs Market by Region: Revenue ($bn), 2018
Figure 6.2: The Hypertension Drugs Market by Region: Market Share (%), 2018
Figure: 6.3 The Hypertension Drugs Market by Country: Revenue ($bn), (%), 2029
Figure 6.4 The Hypertension Drugs Market by Country: Market Share (%), 2029
Figure: 6.5 The US Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.6 Canada Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.7 Mexico Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.8 EU Hypertension Drugs Market by Country: Revenue ($bn), 2018
Figure 6.9 EU Hypertension Drugs Market by Country: Market Share (%), 2018
Figure 6.10 EU Hypertension Drugs Market Forecast by Country: Revenue ($bn) and AGR (%), 2019-2029
CAGR (%), 2019-2029
Figure 6.11 Germany Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.12 France Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.13 UK Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.14 Italy Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.15 Spain Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.16 The ROE Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.17 Japan Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.18 China Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.19 India Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.20 RoA Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.21 The Russia Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.22 Brazil Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.23 South Africa Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 6.24 RoW Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
Figure 7.1 AstraZeneca Financial Performance ($mn), 2015-2017
Figure 7.2 Sanofi Aventis Net Sales ($mn),2015-2017
Figure 7.3 Sanofi Aventis Net Sales by Segments ($mn),2015-2017
Figure 7.4 Daiichi Sankyo Net Revenues: ($mn), (2015-2017)
Figure 7.5 Novartis Revenue ($bn), 2017
Figure 7.6 Novartis Pharmaceutical by Business Segment: Revenue Share (%),2017
Figure 7.7 Pfizer Revenue ($mn): 2015- 2017
Figure 7.8 Merck & Co. Revenue ($mn): 2015- 2017
Figure 7.9 Boehringer Ingelheim & Co. Revenue ($mn): 2016- 2017
Figure 7.10 United Therapeutics Revenue ($mn): 2015- 2017
Figure 8.1. Pulmonary Hypertension Clinical Trials
Figure 8.2. Essential Hypertension Clinical Trials
